The Huntsman Cancer Institute in Vineyard marks the start of vertical construction, aiming to ease travel burden for cancer patients in Utah County and beyond. The 284,000-square-foot campus will expand comprehensive cancer care, research, education, and innovation services.
A new drug, daraxonrasib, has been identified as a potential treatment for patients with NRAS-driven melanoma. The therapy targets and inhibits RAS protein, which drives cancer growth when mutated. Early results from preclinical models suggest the drug may be effective in treating advanced disease.
The state of Utah has invested over $33 million in artificial intelligence and computing initiatives to advance health and discovery. The investments will enable a new AI supercomputer accessible to all state universities, accelerating breakthroughs in prevention, early detection, personalized treatments, and survivorship across numero...
A new combination treatment of eflornithine and lomustine has been shown to improve overall survival rates for patients with grade 3 astrocytoma by about 35 months compared to standard treatment. Patients with grade 4 IDH-mutant astrocytoma or glioblastoma did not benefit from the new therapy.
The institute has opened its first specialized angiography-CT suite, integrating two forms of imaging equipment in one dedicated space. This allows interventional radiologists to perform both angiography and CT scans on the same day, reducing travel burdens for patients and improving treatment outcomes.
A study by Huntsman Cancer Institute found that triple-negative breast cancer is fueled by lipids and that these fatty acids promote tumor growth. The research suggests that breast cancer patients and survivors with obesity could benefit from lipid-lowering therapies.
Neli Ulrich, a leading epidemiologist, has been elected as vice president and president-elect of the AACI Board of Directors. She will serve for two years before assuming the presidency of the organization, with a focus on advancing cancer research, prevention, and care.
Research from Huntsman Cancer Institute found that people with two or more tattoo sessions had a decreased risk of both invasive and in situ melanoma. However, participants with only one tattoo session were more likely to develop melanoma, especially in situ.
The Huntsman Cancer Institute is launching new clinical trials to explore how theranostics can help more patients. Theranostics combines diagnostics and therapeutics to deliver targeted radiation directly to cancer cells, offering a powerful approach to finding and treating cancer.
The expansion of Huntsman Cancer Institute's proton therapy center will double treatment capacity and increase access to life-saving cancer care for patients in Utah, Idaho, Montana, Nevada, and Wyoming. The new center will enable the treatment of more patients and expand proton therapy options for certain types of cancers.
Mary Beckerle is stepping down as Huntsman Cancer Institute's CEO after 20 years of service. Brad Cairns will take over leadership, continuing the institute's mission to eradicate cancer.
Researchers at Huntsman Cancer Institute have developed a new combination drug therapy that prolongs survival rates in preclinical mouse models and prevents brain metastasis. The treatment combines inhibiting the enzyme FAK with an inhibitor of RAF and MEK, components of the current standard-of-care regimen. Additionally, personalized ...
Dr. Alana Welm has been appointed as the Chair of Oncological Sciences, leading efforts to advance research, education, and clinical impact. With a focus on innovation and collaboration, she aims to foster a culture of excellence and position the department for national distinction.
A Phase 1 clinical trial has successfully used banked deceased donor stem cells for an allogeneic transplant, expanding transplant options for patients with aggressive blood cancers. This innovative approach aims to reduce wait times and uncertainty around donor matching and collection.
The new facility will expand capacity for research, care, education, and training, bringing comprehensive cancer care closer to communities. Huntsman Cancer Institute will advance innovative cancer research, train the next generation of scientists and health workers.
A federally funded study by Huntsman Cancer Institute found that 7% of Medicare patients with cancer cross state borders for treatment, with rates nearly double for rural patients. Telehealth can fill gaps in cancer treatment and reduce travel burdens, says senior author Tracy Onega.
A new drug therapy combination inhibiting FAK, RAF, and MEK enzymes has shown promise in prolonging survival rates for preclinical mouse models of metastatic melanoma. The study's findings suggest the oral treatment can both treat and prevent brain metastasis.
Researchers found that Black women have nearly identical mutations to other populations but experience lower survival rates due to clinical factors. The study highlights the importance of studying different population groups to improve ovarian cancer healthcare and develop targeted treatments.
Huntsman Cancer Institute is expanding its services through a new federal contract, introducing a mobile medical vehicle that brings advanced cancer care to rural communities. The program aims to enhance patient access to specialized care and increase participation in clinical trials.
Researchers at Huntsman Cancer Institute found that short-course, higher dose vaginal brachytherapy for endometrial cancer was as effective as more frequent, lower dose sessions in similar outcomes and few acute toxicities. The study aims to improve cancer care for patients across the Mountain West region.
The addition of da Vinci 5 robotic surgical systems at Huntsman Cancer Institute offers enhanced precision and control during minimally invasive surgeries. The system's advanced technology enables complex procedures to be performed through small incisions, reducing hospital stays and accelerating recovery times for patients.
The myeloMATCH program aims to improve precision medicine by matching patients with specific genetic signatures of their disease. Patients receive tailored treatment options based on the unique makeup of their cancer, offering hope for improved outcomes and increased survival rates.
Researchers discovered a gene variant in high-altitude Andean populations that can help predict the severity of certain types of blood cancer. The NFKB1 gene variant is associated with lower inflammation levels and better treatment responses in patients with myeloproliferative neoplasms.
Chelsey Schlechter, an investigator at Huntsman Cancer Institute, has been selected as a Cancer Moonshot Scholar. Her project, SMARTLife Utah, aims to connect patients with evidence-based weight management programs to prevent obesity-related cancers.
The National Cancer Institute has awarded Huntsman Cancer Institute $250,000 to recognize excellence in diversity, equity, inclusion, and accessibility mentorship. The award supports the lab's research on cancer cell division and fosters an inclusive research environment that drives innovation.
Researchers at Huntsman Cancer Institute found that a chatbot can assist patients in deciding whether to pursue genetic testing, offering an alternative to traditional genetic counseling. The study demonstrated equally likely outcomes between the chatbot group and those receiving standard two-appointment model care.
Researchers at Huntsman Cancer Institute have developed a mechanism that accurately forecasts the aggressiveness of triple-negative breast cancer (TNBC). This advancement could allow doctors to identify higher-risk patients and tailor precise treatments.
A recent study published in The Journal of Clinical Endocrinology and Metabolism found that women who underwent menopause before age 46 were nearly twice as likely to develop breast cancer as other women of similar ages. Relatives of these women were also more likely to have breast, prostate, or colon cancer.
A landmark study found women with severe endometriosis have a 10-fold increased risk of ovarian cancer, compared to those without the disease. The study analyzed over 78,000 women and revealed that those with severe endometriosis are also at higher risk for type I ovarian cancer.
Researchers at Huntsman Cancer Institute discovered a surprising connection between male infertility and an increased risk of certain cancers in families. By analyzing genetic and public health data, the team identified 13 characteristic patterns that cluster similar things together, making it easier to uncover the reason behind a fami...
A recent study published in JAMA Internal Medicine found that only 18% of physicians portrayed in films are women, despite increasing representation over time. The research highlights the importance of media representation in shaping attitudes towards women in medicine and may contribute to imposter syndrome among underrepresented groups.
Researchers at Huntsman Cancer Institute found that increasing access to care for Black people with prostate cancer could decrease mortality rates. The institute is also conducting a clinical trial for small cell lung cancer and developing an app to help adolescents manage cancer symptoms.
A study published in Pediatrics found that texting can increase participation in public health programs, with 99% of staff having a valid cell phone number and fewer than 4% opting out. The SCALE-UP Counts program showed that texting can reach staff in K-12 schools to provide health screening messages.
Researchers at Huntsman Cancer Institute discovered that estrogen receptor mutations in endometrial cancers cause large changes in gene expression and cellular behavior. Inhibitors of CDK9, a protein that works with estrogen receptors, were found to be effective at reducing the growth and aggressiveness of endometrial cancer cells.
A new prostate cancer treatment combining enzalutamide and talazoparib has been approved by the FDA, offering improved patient outcomes. The treatment was found to decrease the risk of cancer progression by 55% in a phase 3 trial.
Researchers have identified a potential breakthrough in glioblastoma treatment, combining a novel viral therapy with a checkpoint inhibitor to attack tumor cells. In phase 2 trials, around 10% of patients showed significant tumor shrinkage and improved overall survival, offering hope for better treatment options.
Researchers found that young adults with previously had cancer have a 70% increased risk for HPV-related cancers. This includes oropharyngeal cancers and cervical HPV-related cancers, particularly among Hispanic survivors.
Researchers discovered how a signaling pathway protein causes tumor growth and resistance to drugs. By understanding this mechanism, they hope to create more effective cancer treatments and improve patient outcomes.
A new study published in the Journal of Clinical Oncology found that frequent aspirin use is linked with a 13% reduced risk of ovarian cancer in individuals with multiple risk factors. Aspirin benefitted most subgroups, including those with endometriosis and obesity.
Researchers from Huntsman Cancer Institute have evaluated the impact of hundreds of different mutations on a key function of the BRCA1 protein. They found that most mutations are either benign or likely benign, while few cause disease. The study aims to improve doctors' ability to assess patients' cancer risk based on genetic testing.
A research team at Huntsman Cancer Institute has developed new methods to identify personalized drug treatments for breast cancer. They have created a way to narrow the number of drugs that might be effective in each tumor based on its unique characteristics and behavior in laboratory models.
Researchers found that environmental signals affect melanocytes, causing them to divide uncontrollably and turn into melanoma. The study provides a foundation for researching potential biomarkers and topical agents to prevent or treat melanoma.
Researchers at Huntsman Cancer Institute have generated the first 'atlas' of human melanocytes, revealing different types and their associations with various skin tones, subtypes of melanoma, and treatment responses. These discoveries aim to improve targeted treatments for melanoma.
Researchers found that patients with both a 22q11.22 deletion and IKZF1 changes had the worst outcomes in childhood leukemia, including almost twice the risk of relapse. The study also suggests that kids with double-deleted leukemia may need more aggressive treatment.
A new study found that one-third of popular cancer treatment articles on social media contain misinformation, which can negatively impact patient outcomes. The vast majority of this misinformation garners more attention and engagement than evidence-based information.
Researchers at Huntsman Cancer Institute have identified a specific gene-regulating protein complex to target in the treatment of synovial sarcoma. The study provides new understanding of how the disease develops and spreads, offering potential breakthroughs in diagnosis and therapy.
A new study published in the Journal of Clinical Oncology reports findings on Huntsman at Home, a cancer hospital-at-home model that demonstrates lower costs and better outcomes for patients. The study found that participants had 55% fewer hospitalizations and 47% lower healthcare costs compared to those who did not participate.
Researchers at Huntsman Cancer Institute discovered that nicotinamide phosphoribosyltransferase (NAMPT) plays a key role in how immune cells fight melanoma tumors. The study found that disrupting the NAMPT pathway impairs antitumor function, and novel therapies targeting this pathway may lead to improved outcomes for patients.
Utah researchers identify mutation hotspots and find that approximately 2% of healthy participants had the same mutations as cancer patients. This study provides new insights into the development of blood cancers and may help identify people at risk.
Researchers at Huntsman Cancer Institute have identified a potential drug combination to treat uveal melanoma by targeting genes GNAQ and GNA11. The study showed that using trametinib and hydroxychloroquine together led to more cell deaths than the drugs alone.